Showing results (281-290 of 376) with videos related to

Sort By:
Pageof 38
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2026
Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance ProfileLuise Rogg, Sebastian A Nuñez, María Verónica Mingrone, et al.
The Lancet. HIV|October 16, 2021
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort studyDaniel K Nomah, Juliana Reyes-Urueña, Yesika Díaz, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 14, 2005
[Changing trends in HIV epidemics: recent diagnoses in the Spanish VACH cohort (2000-2002)]Ramón Teira, Ignacio Suárez-Lozano, Pepa Muñoz, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsJuan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2020
Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)Arkaitz Imaz, Juan M Tiraboschi, Jordi Niubó, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2022
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254Christoph D Spinner, Franco Felizarta, Giuliano Rizzardini, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2024
Major cardiovascular events after COVID-19 in people with HIVRaquel Martín-Iguacel, Sergio Moreno-Fornés, Andreu Bruguera, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
Pageof 38